GlassScriptPhysician profile
Cara J Barlis
NPI 1356486518
$2,100.74
in general payments reported to CMS, 2019-2025
31 companies · $470 in 2025
The $470 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $522 · 2020: $113 · 2021: $128 · 2022: $247 · 2023: $286 · 2024: $334 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,090.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $259.51 | 2019-2025 | General - Pain Management |
| Novo Nordisk INC | $217.29 | 2022-2025 | Wegovy, Saxenda |
| Pfizer INC. | $196.07 | 2019-2025 | |
| Abbvie INC. | $169.21 | 2021-2024 | Ubrelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $147.69 | 2019-2025 | Trintellix |
| Depuy Synthes Sales INC. | $127.42 | 2021-2024 | Orthovisc, Monovisc |
| Bioventus LLC | $111.57 | 2019-2025 | Xcell, Durolane |
| Exact Sciences Corporation | $99.71 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $97.57 | 2021-2025 | |
| Pacira Therapeutics, INC. | $91.71 | 2019-2020 | |
| Lilly USA, LLC | $67.80 | 2020-2025 | Mounjaro |
| Globus Medical, INC. | $55.03 | 2025 | Senza |
| Astrazeneca Pharmaceuticals LP | $53.25 | 2019-2024 | Airsupra |
| Ferring Pharmaceuticals INC. | $51.09 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $38.01 | 2019-2023 | Austedo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $29.71 | 2019 | |
| Allergan, INC. | $29.07 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $28.95 | 2023-2025 | Contrave |
| Vertical Pharmaceuticals, LLC | $28.47 | 2019 | |
| Amgen INC. | $28.01 | 2019-2024 | Otezla, Repatha |
| Astellas Pharma US INC | $22.36 | 2025 | Veozah |
| Fidia Pharma USA INC. | $19.44 | 2020 | |
| Glaxosmithkline, LLC. | $18.43 | 2025 | Shingrix |
| Zyla Life Sciences, INC. | $16.25 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.40 | 2025 | |
| Ibsa Pharma INC. | $14.97 | 2022 | |
| Sanofi Pasteur INC. | $14.67 | 2022 | |
| Mayne Pharma Commercial LLC | $14.32 | 2022 | |
| Exeltis, USA INC. | $13.71 | 2021 | |
| Seqirus USA INC | $12.26 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cara Barlis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.